title: Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.
abstract: Prognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at 10 European oncology units (no prior treatment: 236; prior radiotherapy: 50). Previously irradiated patients displayed a 69% PFS as compared to 87% in those presenting with advanced seminoma at the time of diagnosis (P = 0.009). In the univariate analysis, the extent and site of disease before chemotherapy and the level of serum LDH (< 2.0 versus > or = 2.0 x upper limit of normal) correlated with PFS in previously non-irradiated patients, but not in patients with prior radiotherapy. The multivariate analysis was, therefore, restricted to previously non-irradiated patients. The presence of non-pulmonary visceral metastases and a serum LDH level of > or = 2 x normal (N) proved to be independent prognostic factors. Based on these variables, two prognostic models were constructed and validated in an external data set of 166 comparable patients. For clinical use, Model 2 is recommended. The good-prognosis group comprises non-irradiated patients with stage II seminoma and any LDH level at presentation, or stage III and IV patients (with lung metastases only) whose serum LDH level is < 2 x N. These patients display a 94% 3-year PFS. The poor prognosis group includes all other patients with a 56% PFS. With this prognostic model, individualisation of the therapeutic approach may be considered in patients with advanced seminoma and a high risk of chemotherapy-related toxicity.
authors.affiliation: Norwegian Radium Hospital, Department of Medical Oncology, Montebello, Oslo, Norway.
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: S P
authors.initials: SP
authors.lastname: Stenning
authors.forename: A
authors.initials: A
authors.lastname: Horwich
authors.forename: P
authors.initials: P
authors.lastname: Wilkinson
authors.forename: G
authors.initials: G
authors.lastname: Read
authors.forename: G M
authors.initials: GM
authors.lastname: Mead
authors.forename: J T
authors.initials: JT
authors.lastname: Roberts
authors.forename: G
authors.initials: G
authors.lastname: Rustin
authors.forename: M H
authors.initials: MH
authors.lastname: Cullen
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: S J
authors.initials: SJ
authors.lastname: Harland
authors.forename: P
authors.initials: P
authors.lastname: Cook
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D018239:Seminoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary*; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D007770:L-Lactate Dehydrogenase; D002945:Cisplatin